Lauren Shea
Hematology & Oncology · Birmingham, ALNPI 1710397880
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $5,670 of the $7,388 with a category attached, or 76.8%. Acrotech Biopharma Inc. accounts for 95.7% of it on its own, with 5 other manufacturers making up the rest. That places this record below the midpoint for hematology & oncology clinicians in AL, where the typical reported total is $7,159.
Across 17 payments — averaging $434.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Acrotech Biopharma Inc.$7K
- Kyowa Kirin, Inc.$103
- Incyte Corporation$100
- Ipsen Biopharmaceuticals, Inc$61
- Gilead$34
- ADC Therapeutics America, Inc.$20
Across 7 payments — averaging $56,833 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Ipsen Biopharmaceuticals, Inc$398K
What the payments were for
- Consulting fees$5,67077%
- Travel & lodging$1,13015%
- Food & beverage$4035%
- Education$1842%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Acrotech Biopharma Inc. | 10 | $7,070 |
| Kyowa Kirin, Inc. | 2 | $103 |
| Incyte Corporation | 1 | $100 |
| Ipsen Biopharmaceuticals, Inc | 1 | $61 |
| Gilead | 2 | $34 |
| ADC Therapeutics America, Inc. | 1 | $20 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Beleodaq$7,009
How this compares
$7,388 in reported general payments places this provider in the 50th percentile of 177 hematology & oncology providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CalquenceAcalabrutinib Maleate | 14 | $202,056 |
| Atovaquone | 15 | $10,978 |
| Acyclovir | 110 | $1,173 |
| Oxycodone Hcl | 31 | $389 |
| Gabapentin | 35 | $320 |
| Pregabalin | 12 | $231 |
| Ondansetron Hcl | 21 | $224 |
| Temazepam | 11 | $165 |
| Prednisone | 34 | $160 |
| Potassium Chloride | 12 | $158 |
| Levothyroxine Sodium | 32 | $152 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 46 | $136 |
| Pantoprazole Sodium | 18 | $117 |
| Duloxetine Hcl | 12 | $103 |
| Dexamethasone | 11 | $80 |
Paid to pharmacies, not to this prescriber.
Other hematology & oncology in Birmingham
- Amitkumar MehtaBirmingham$683K
- Pankit VachhaniBirmingham$545K
- Luciano CostaBirmingham$409K
- Khaleel AshrafBirmingham$379K
- Michael BirrerBirmingham$302K
- Rudolph NavariBirmingham$254K
- Mayur NarkhedeBirmingham$193K
- Midhun MallaBirmingham$144K
- Robert ConryBirmingham$143K
- David MooneyBirmingham$120K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.